We have updated our forecasts on Oxford BioMedica this morning following full year results and portfolio review on 28 April 2015. We have increased our revenue forecasts in 2016 and 2017 however, the increase in administrative expenses more than offsets this, resulting in reduced LBT forecasts. Despite raising £8.1m in Q1 2016, the group currently only has sufficient cash resources into Q3 2016. We remain concerned about the group’s ability to maintain cash and cash equivalents of at least $10m ....
